Yamamoto C, Narita N
Second Department of Internal Medicine, Nara Medical University.
Nihon Rinsho. 1996 Nov;54(11):3087-92.
Treatment with inhaled steroid has become increasingly important in asthma. However there are also many patients with asthma whose symptoms are uncontrolled by beclomethasone dipropionate (BDP) alone. For these patients we have tried the regular use of inhaled procaterol or inhaled fenoterol with BDP, and some of these patients have got good control. Recent studies show that, in patients whose asthma is inadequately controlled with BDP, better control can be achieved by adding inhaled long-acting beta 2-agonist rather than by doubling the dose of BDP. In the near future inhaled long-acting beta 2-agonist will be possible for clinical use in our country, and the combined use of it and BDP as preventive therapy will be the mainstay of treatment for patients with moderate-to-severe asthma.
吸入性类固醇治疗在哮喘治疗中变得越来越重要。然而，也有许多哮喘患者仅使用二丙酸倍氯米松（BDP）无法控制症状。对于这些患者，我们尝试让他们定期联合吸入丙卡特罗或非诺特罗与BDP，其中一些患者病情得到了良好控制。最近的研究表明，在使用BDP控制不佳的哮喘患者中，添加吸入性长效β2受体激动剂比加倍BDP剂量能更好地控制病情。在不久的将来，吸入性长效β2受体激动剂将有可能在我国临床应用，并且它与BDP联合作为预防性治疗将成为中重度哮喘患者治疗的主要方法。
